

Part VI: Summary of the risk management plan

Summary of risk management plan for Acitretin Orifarm (acitretin)

This is a summary of the risk management plan (RMP) for Acitretin Orifarm. The RMP details important risks of Acitretin Orifarm, how these risks can be minimised, and how more information will be obtained about Acitretin Orifarm's risks and uncertainties (missing information).

Acitretin Orifarm's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Acitretin Orifarm should be used.

Important new concerns or changes to the current ones will be included in updates of Acitretin Orifarm's RMP.

I. The medicine and what it is used for

Acitretin Orifarm is authorised for extensive psoriasis, invalidating pustolus psoriasis and invalidating Darier's disease in adults (see SmPC for the full indication). It contains acitretin as the active substance and it is given by the oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Acitretin Orifarm, together with measures to minimise such risks and the proposed studies for learning more about Acitretin Orifarm's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Acitretin Orifarm, these measures are supplemented with *additional risk minimisation measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Acitretin Orifarm are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Acitretin Orifarm. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Teratogenicity
Important potential risks	• Psychiatric disorders – including depression, suicidality and anxiety
Missing information	None

II.B Summary of important risks

Teratogenicity	
Risk minimisation measures	Routine risk minimisation measures SmPC section 4.2, 4.3, 4.4, 4.5, 4.6, 5.2 and 5.3. SmPC section 4.4 with recommendation for medically supervised pregnancy testing before, during and 3 years after the end of treatment and documenting the dates and results of pregnancy testing. Warning box at the beginning of the PL and PL section 2. Prescription status limited to dermatologists and physicians with experience in use of systemic retinoids. Additional risk minimisation measures Pregnancy Prevention Programme consisting of the following educational material: • <i>Prescriber checklist/acknowledgement form</i> • <i>Patient reminder card</i> • <i>Pharmacist checklist</i>
Additional pharmacovigilance activities	Additional pharmacovigilance activities: A qualitative study on Health Care Professionals (HCPs) and Patients' perceptions, behaviors, perspectives, and barriers

	on the implementation of the PPPSee section II.C of this summary for an overview of the post-authorisation development plan.
--	--

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Acitretin Orifarm.

II.C.2 Other studies in post-authorisation development plan

Qualitative study

Purpose of the study: The overall aim of this study is to identify, qualify and describe the barriers and reasons for insufficient compliance to the oral retinoid therapy PPP by HCPs who prescribe or dispense oral retinoid therapy and women of childbearing potential treated with oral retinoid therapy in Europe.